SK283584B6 - Farmaceutický prostriedok s antivírusovým účinkom obsahujúci kyselinu glycyrhizovú a aspoň jeden proteín prejavujúci antivírusový účinok - Google Patents
Farmaceutický prostriedok s antivírusovým účinkom obsahujúci kyselinu glycyrhizovú a aspoň jeden proteín prejavujúci antivírusový účinok Download PDFInfo
- Publication number
- SK283584B6 SK283584B6 SK1544-99A SK154499A SK283584B6 SK 283584 B6 SK283584 B6 SK 283584B6 SK 154499 A SK154499 A SK 154499A SK 283584 B6 SK283584 B6 SK 283584B6
- Authority
- SK
- Slovakia
- Prior art keywords
- lysozyme
- lactoferrin
- glycyrrhizic acid
- chicken
- inhibition
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- 239000002253 acid Substances 0.000 title abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 230000002195 synergetic effect Effects 0.000 claims abstract description 5
- 235000010335 lysozyme Nutrition 0.000 claims description 39
- 108010014251 Muramidase Proteins 0.000 claims description 34
- 102000016943 Muramidase Human genes 0.000 claims description 34
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 34
- 229960000274 lysozyme Drugs 0.000 claims description 34
- 239000004325 lysozyme Substances 0.000 claims description 34
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 28
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 28
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 28
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 28
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 28
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 28
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 28
- 241000287828 Gallus gallus Species 0.000 claims description 22
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 17
- 235000021242 lactoferrin Nutrition 0.000 claims description 17
- 102000010445 Lactoferrin Human genes 0.000 claims description 15
- 108010063045 Lactoferrin Proteins 0.000 claims description 15
- 229940078795 lactoferrin Drugs 0.000 claims description 15
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 14
- 210000003501 vero cell Anatomy 0.000 claims description 9
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 102000050459 human LTF Human genes 0.000 claims description 7
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 claims description 6
- 239000002356 single layer Substances 0.000 claims description 6
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 229940072440 bovine lactoferrin Drugs 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- -1 alkaline earth metal salt Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 5
- 208000036142 Viral infection Diseases 0.000 abstract description 2
- 230000009385 viral infection Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 3
- 208000035415 Reinfection Diseases 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 230000003602 anti-herpes Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241001414890 Delia Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI001119A IT1291366B1 (it) | 1997-05-14 | 1997-05-14 | Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale |
| PCT/EP1998/002797 WO1998051334A1 (en) | 1997-05-14 | 1998-05-06 | Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK154499A3 SK154499A3 (en) | 2000-08-14 |
| SK283584B6 true SK283584B6 (sk) | 2003-10-07 |
Family
ID=11377123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1544-99A SK283584B6 (sk) | 1997-05-14 | 1998-05-06 | Farmaceutický prostriedok s antivírusovým účinkom obsahujúci kyselinu glycyrhizovú a aspoň jeden proteín prejavujúci antivírusový účinok |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6329339B1 (OSRAM) |
| EP (1) | EP0980254B1 (OSRAM) |
| JP (2) | JP2001525814A (OSRAM) |
| KR (1) | KR100592193B1 (OSRAM) |
| CN (1) | CN1114447C (OSRAM) |
| AR (1) | AR012849A1 (OSRAM) |
| AT (1) | ATE212232T1 (OSRAM) |
| AU (1) | AU740944B2 (OSRAM) |
| BG (1) | BG64748B1 (OSRAM) |
| CA (1) | CA2289550A1 (OSRAM) |
| CZ (1) | CZ291932B6 (OSRAM) |
| DE (1) | DE69803565T2 (OSRAM) |
| DK (1) | DK0980254T3 (OSRAM) |
| EA (1) | EA003126B1 (OSRAM) |
| ES (1) | ES2170501T3 (OSRAM) |
| GE (1) | GEP20022672B (OSRAM) |
| HU (1) | HU224956B1 (OSRAM) |
| IL (2) | IL132651A0 (OSRAM) |
| IT (1) | IT1291366B1 (OSRAM) |
| PL (1) | PL189218B1 (OSRAM) |
| PT (1) | PT980254E (OSRAM) |
| SK (1) | SK283584B6 (OSRAM) |
| TR (1) | TR199902730T2 (OSRAM) |
| UA (1) | UA63955C2 (OSRAM) |
| WO (1) | WO1998051334A1 (OSRAM) |
| ZA (1) | ZA983917B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7151082B2 (en) * | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| AU2003225073A1 (en) * | 2002-04-18 | 2003-11-03 | The University Of Iowa Research Foundation | Methods of inhibiting and treating bacterial biofilms by metal chelators |
| US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| CA2882022A1 (en) * | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| US7964706B2 (en) * | 2004-10-22 | 2011-06-21 | Medimmune, Llc | High affinity antibodies against HMGB1 and methods of use thereof |
| WO2007011606A2 (en) * | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| IT1391170B1 (it) * | 2008-08-07 | 2011-11-18 | D M G Italia S R L | Composizione topica intra-nasale utilizzabile in caso di ostruzione nasale |
| CA2809031C (en) * | 2010-08-25 | 2018-10-16 | Weijian Zhang | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| US9416151B2 (en) | 2010-08-25 | 2016-08-16 | Lurong ZHANG | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| US20170049863A1 (en) * | 2014-02-21 | 2017-02-23 | National University Corporation Tokyo University Of Marine Science And Technology | Norovirus deactivator and method for producing same, method for deactivating norovirus, method for producing lysozyme component for norovirus deactivation use, prophylactic or therapeutic agent for norovirus infection, and external preparation for skin for norovirus deactivation purposes |
| US12447166B2 (en) | 2016-02-25 | 2025-10-21 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
| SG11201806868TA (en) * | 2016-02-25 | 2018-09-27 | Applied Biological Laboratories Inc | Compositions and methods for protecting against airborne pathogens and irritants |
| CN109022351B (zh) * | 2018-09-28 | 2021-10-19 | 广州奇龙生物科技有限公司 | 重组人溶菌酶的新应用 |
| EP3928785B1 (en) * | 2020-04-27 | 2024-07-31 | Guangzhou Century Clinical Research Co., Ltd | Medicament and food for use in preventing or treating novel coronavirus pneumonia covid-19 |
| CN112135625B (zh) * | 2020-04-27 | 2021-07-06 | 广州新创忆药物临床研究有限公司 | 一种预防或治疗covid-19新冠肺炎的药物及其应用 |
| JP7543427B2 (ja) * | 2020-04-27 | 2024-09-02 | 広州新創憶薬物臨床研究有限公司 | 抗新型コロナウイルス感染症の医薬品、食品、及び使用 |
| MX2021005280A (es) * | 2021-05-04 | 2022-02-23 | Spv Timser S A P I De C V | Composicion farmaceutica que contiene triterpenoides pentaciclicos. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH085800B2 (ja) * | 1986-12-19 | 1996-01-24 | エーザイ株式会社 | 塩化リゾチ−ム及びグリチルリチン酸ジカリウム含有水溶液製剤 |
| JP2838720B2 (ja) * | 1989-10-31 | 1998-12-16 | ゼリア新薬工業株式会社 | 安定な点眼剤 |
| JP4056099B2 (ja) * | 1996-05-09 | 2008-03-05 | 森永乳業株式会社 | 水生動物の寄生生物性疾患の予防および治療剤 |
-
1997
- 1997-05-14 IT IT97MI001119A patent/IT1291366B1/it active IP Right Grant
-
1998
- 1998-05-06 GE GEAP19985126A patent/GEP20022672B/en unknown
- 1998-05-06 PL PL98336802A patent/PL189218B1/pl not_active IP Right Cessation
- 1998-05-06 WO PCT/EP1998/002797 patent/WO1998051334A1/en not_active Ceased
- 1998-05-06 CZ CZ19993991A patent/CZ291932B6/cs not_active IP Right Cessation
- 1998-05-06 TR TR1999/02730T patent/TR199902730T2/xx unknown
- 1998-05-06 AT AT98925588T patent/ATE212232T1/de not_active IP Right Cessation
- 1998-05-06 DK DK98925588T patent/DK0980254T3/da active
- 1998-05-06 ES ES98925588T patent/ES2170501T3/es not_active Expired - Lifetime
- 1998-05-06 JP JP54879998A patent/JP2001525814A/ja not_active Ceased
- 1998-05-06 CN CN98805037A patent/CN1114447C/zh not_active Expired - Fee Related
- 1998-05-06 SK SK1544-99A patent/SK283584B6/sk not_active IP Right Cessation
- 1998-05-06 EA EA199901024A patent/EA003126B1/ru not_active IP Right Cessation
- 1998-05-06 EP EP98925588A patent/EP0980254B1/en not_active Expired - Lifetime
- 1998-05-06 HU HU0002985A patent/HU224956B1/hu not_active IP Right Cessation
- 1998-05-06 US US09/423,611 patent/US6329339B1/en not_active Expired - Fee Related
- 1998-05-06 PT PT98925588T patent/PT980254E/pt unknown
- 1998-05-06 DE DE69803565T patent/DE69803565T2/de not_active Expired - Fee Related
- 1998-05-06 KR KR1019997010372A patent/KR100592193B1/ko not_active Expired - Fee Related
- 1998-05-06 IL IL13265198A patent/IL132651A0/xx active IP Right Grant
- 1998-05-06 AU AU77646/98A patent/AU740944B2/en not_active Ceased
- 1998-05-06 CA CA002289550A patent/CA2289550A1/en not_active Abandoned
- 1998-05-08 ZA ZA983917A patent/ZA983917B/xx unknown
- 1998-05-13 AR ARP980102218A patent/AR012849A1/es active IP Right Grant
- 1998-06-05 UA UA99126790A patent/UA63955C2/uk unknown
-
1999
- 1999-10-29 IL IL132651A patent/IL132651A/en not_active IP Right Cessation
- 1999-12-08 BG BG103968A patent/BG64748B1/bg unknown
-
2008
- 2008-12-25 JP JP2008331229A patent/JP2009102370A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK283584B6 (sk) | Farmaceutický prostriedok s antivírusovým účinkom obsahujúci kyselinu glycyrhizovú a aspoň jeden proteín prejavujúci antivírusový účinok | |
| Marchetti et al. | Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2 | |
| Lampis et al. | Enhancement of anti-herpetic activity of glycyrrhizic acid by physiological proteins | |
| US4462986A (en) | Synergistic anti-herpes compositions | |
| JP2023123440A (ja) | 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物 | |
| CA2109435C (en) | Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals | |
| US4957733A (en) | Pharmaceutical products | |
| TW372193B (en) | Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient | |
| US4828830A (en) | Method and composition for prophylaxis and treatment of viral infections | |
| Lefkowitz et al. | Comparative effectiveness of six antiviral agents in herpes simplex type I infection of mice | |
| MXPA99010447A (en) | Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity | |
| AU2734095A (en) | A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof | |
| HK1028347B (en) | Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity | |
| HK40026056A (en) | Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics | |
| KR20220054586A (ko) | 항바이러스 조성물 | |
| EP3964196A1 (en) | Use of chlorhexidine and cetylpyridinium chloride as antiviral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20090506 |